Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.
Feature|Articles|August 26, 2026
Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations
Author(s)Raviv Pryluk
Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk.
Advertisement
Advertisement
Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your biostatistician pulls up a standard power calculation, someone picks an effect size that feels reasonable, say, a 30% improvement over placebo, and the software produces a sample size. The meeting ends. The number gets locked in.
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
Advertisement
Advertisement